The FDA cleared Neosoma's Brain Mets software on December 17, 2025, an AI tool that detects, measures, and contours an unlimited number of brain metastases from standard MRI scans for radiation therapy planning.
Takeda signed a collaboration worth up to $600 million with Insilico Medicine on July 3, 2026, tapping the company's generative AI drug-discovery platform to find new molecules—part of a $7 billion deal-making sprint that has investors excited and skeptics waiting for actual approvals.
Recursion Pharmaceuticals says REC-4881, a drug its AI platform found through unbiased cell-imaging screens rather than a predetermined target, cut polyp burden by more than half in patients with familial adenomatous polyposis, a disease with no approved drug treatment.
George Mason University's Injury Analytics Lab has patented an AI system that adjusts imaging to skin tone and combines it with electronic health record data to detect and assess bruises more consistently, aiming to close a long-documented equity gap in injury detection.
Twelve major US health systems, together caring for nearly 20 million patients a year, have joined Aidoc to form a Diagnostic AI Consortium aimed at building shared standards for how diagnostic AI is evaluated and governed across hospitals.
Samsung and Massachusetts General Hospital's Diabetes Research Center are testing whether Galaxy Watch8 sensors and AI-guided coaching can help patients on GLP-1 drugs preserve muscle mass, validating wearable data against clinical DXA scans.
An NIH-funded study used deep learning to analyze thrice-daily smartphone surveys from 62 patients in opioid addiction treatment, accurately forecasting relapse risk hours to days in advance, though researchers caution the small, non-diverse sample needs broader validation.
An AI tool embedded in Epic at NewYork-Presbyterian and Weill Cornell Medicine flags pregnant patients at risk for postpartum depression during routine prenatal visits, part of a wider 2026 research push toward predicting the condition before it starts.
A new Harvard-developed AI model called popEVE has flagged 123 previously unknown disease genes in a cohort of 30,000 undiagnosed patients, with 25 already confirmed by independent labs, offering a new path through the years-long diagnostic odyssey many rare disease families face.
Whoop is adding on-demand video visits with licensed clinicians alongside new AI coaching features that let its algorithm remember a user's real-life context, a move that pits it directly against rival Oura's new AI health assistant.